Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · IEX Real-Time Price · USD
32.04
-0.58 (-1.78%)
At close: Jul 2, 2024, 4:00 PM
31.16
-0.88 (-2.75%)
After-hours: Jul 2, 2024, 5:48 PM EDT
Collegium Pharmaceutical Revenue
Collegium Pharmaceutical had revenue of $566.92M in the twelve months ending March 31, 2024, with 8.00% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $144.92M with 0.11% year-over-year growth. In the year 2023, Collegium Pharmaceutical had annual revenue of $566.77M with 22.17% growth.
Revenue (ttm)
$566.92M
Revenue Growth
+8.00%
P/S Ratio
1.85
Revenue / Employee
$2,877,782
Employees
197
Market Cap
1.05B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 566.77M | 102.83M | 22.17% |
Dec 31, 2022 | 463.93M | 187.07M | 67.56% |
Dec 31, 2021 | 276.87M | -33.15M | -10.69% |
Dec 31, 2020 | 310.02M | 13.32M | 4.49% |
Dec 31, 2019 | 296.70M | 16.29M | 5.81% |
Dec 31, 2018 | 280.41M | 251.94M | 884.73% |
Dec 31, 2017 | 28.48M | 26.77M | 1,564.29% |
Dec 31, 2016 | 1.71M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.42B |
Ironwood Pharmaceuticals | 413.55M |
Artivion | 368.21M |
Silk Road Medical | 185.49M |
Calliditas Therapeutics AB (publ) | 119.73M |
Arcutis Biotherapeutics | 106.39M |
Ocular Therapeutix | 59.84M |
Tarsus Pharmaceuticals | 42.56M |
COLL News
- 4 weeks ago - Collegium to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Collegium Announces $35 Million Accelerated Share Repurchase Program - GlobeNewsWire
- 7 weeks ago - Collegium Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 2 months ago - Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 - GlobeNewsWire
- 4 months ago - Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 - GlobeNewsWire
- 7 months ago - Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent - GlobeNewsWire